Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options

Authors

  • Blair Egerdie Vice President Medical, St. Mary’s General Hospital, Adjunct Professor of Urology, The University of Western Ontario, London, ON
  • Fred Saad Professor and Chairman of Urology, Centre hospitalier de l’Université de Montréal, Université de Montréal Endowed Chair in Prostate Cancer, Université de Montréal, Montréal, QC

DOI:

https://doi.org/10.5489/cuaj.811

Abstract

Osteoporosis and bone fractures are frequently overlooked complications
of androgen deprivation therapy in men with nonmetastatic
prostate cancer. All such patients should have their bone mineral
density (BMD) monitored and be offered preventive measures,
such as calcium and vitamin D supplementation; patients with
low BMD should be offered treatment. Several agents, including
bisphosphonates, are available (although this use is currently offlabel),
and upcoming treatments, such as denosumab and toremifene,
have shown promise in reducing fracture risk in these patients.

L’ostéoporose et les fractures osseuses sont des complications souvent
négligées du traitement antiandrogénique chez les hommes
atteints d’un cancer de la prostate non métastatique. La teneur
minérale des os de ces patients devrait être surveillée, et des mesures
préventives, comme la prise de suppléments de calcium et de vita -
mine D, devraient être offertes. Les patients présentant une faible
teneur minérale des os devraient se voir offrir un traitement approprié.
Plusieurs agents, y compris des bisphosphonates, sont offerts
sur le marché (quoique cette indication ne soit pas officiellement
approuvée à l’heure actuelle), et des traitements en cours d’étude,
comme le dénosumab et le torémifène, se sont révélés prometteurs
dans la réduction du risque de fracture chez ces patients.

Downloads

Download data is not yet available.

Author Biographies

Blair Egerdie, Vice President Medical, St. Mary’s General Hospital, Adjunct Professor of Urology, The University of Western Ontario, London, ON

Fred Saad, Professor and Chairman of Urology, Centre hospitalier de l’Université de Montréal, Université de Montréal Endowed Chair in Prostate Cancer, Université de Montréal, Montréal, QC

Downloads

How to Cite

Egerdie, B., & Saad, F. (2013). Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options. Canadian Urological Association Journal, 4(2), 129–135. https://doi.org/10.5489/cuaj.811

Issue

Vol. 4 No. 2 (2010): CUAJ April

Section

Review

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.